FDA Walks Back Claim of Dramatic Benefit From Blood Plasma Covid Therapy

The head of the U.S. Food and Drug Administration walked back his claim that an experimental therapy had provided a dramatic benefit to Covid-19 patients, a rare reversal for an agency that has prided itself on rock-solid science and public trust.

On Sunday night at a press conference with President Donald Trump, FDA Commissioner Stephen Hahn said that blood plasma from Covid-19 survivors given to new patients could save huge numbers of lives.

“What that means is -- and if the data continue to pan out -- 100 people who are sick with Covid-19, 35 would have been saved because of the administration of plasma,” Hahn said. Hahn’s remarks followed similar comments by Trump, who said that the therapy is “proven to reduce mortality by 35%,” and by Health and Human Services Secretary Alex Azar.

On Monday night, Hahn reversed himself.

“I have been criticized for remarks I made Sunday night about the benefits of convalescent plasma. The criticism is entirely justified,” Hahn said in a tweet. He went on CBS on Tuesday morning to continue walking back the claim, telling the network that “I could have done a better job of explaining that at the press conference.”

Subscribe to our YouTube channel

QUICKTAKE ON SOCIAL:

Follow QuickTake on Twitter: twitter.com/quicktake

Like QuickTake on Facebook: facebook.com/quicktake

Follow QuickTake on Instagram: instagram.com/quicktake

Subscribe to our newsletter

Email us at quicktakenews@gmail.com

QuickTake by Bloomberg is a global news network delivering up-to-the-minute analysis on the biggest news, trends and ideas for a new generation of leaders.